Louise E Donnelly

List of Publications by Year
in descending order

92	6,656	57681	73587
papers	citations	46 h-index	79 g-index

116	116	116	9161
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bacterial Colonization in COPD. , 2022, , 573-582.		0
2	Update in Chronic Obstructive Pulmonary Disease 2020. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 14-22.	2.5	9
3	Defective monocyte-derived macrophage phagocytosis is associated with exacerbation frequency in COPD. Respiratory Research, 2021, 22, 113.	1.4	21
4	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 763-772.	5.2	301
5	Leukocyte Function in COPD: Clinical Relevance and Potential for Drug Therapy. International Journal of COPD, 2021, Volume 16, 2227-2242.	0.9	6
6	Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model. Journal of Immunology, 2020, 205, 2489-2498.	0.4	13
7	Update in Chronic Obstructive Pulmonary Disease 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 348-355.	2.5	20
8	Targeting defective pulmonary innate immunity â€“ A new therapeutic option?. , 2020, 209, 107500.		26
9	Senotherapy. Chest, 2020, 158, 562-570.	0.4	44
10	Defective bacterial phagocytosis is associated with dysfunctional mitochondria in COPD macrophages. European Respiratory Journal, 2019, 54, 1802244.	3.1	86
11	Update in Asthma and Airway Inflammation 2018. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 14-19.	2.5	5
12	Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 556-564.	2.5	282
13	The ERS fellowship portfolio: fostering excellence and diversity. European Respiratory Journal, 2019, 54, 1901503.	3.1	3
14	MicroRNAâ€570 is a novel regulator of cellular senescence and inflammaging. FASEB Journal, 2019, 33, 1605-1616.	0.2	64
15	Human Rhinovirus Impairs the Innate Immune Response to Bacteria in Alveolar Macrophages in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1496-1507.	2.5	42
16	Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 445-453.	1.4	35
17	Galectin-3 enhances monocyte-derived macrophage efferocytosis of apoptotic granulocytes in asthma. Respiratory Research, 2019, 20, 1.	1.4	104
18	Bacterial load and defective monocyte-derived macrophage bacterial phagocytosis in biomass smoke-related COPD. European Respiratory Journal, 2019, 53, 1702273.	3.1	30

#	Article	IF	Citations
19	Reduced Clearance of Fungal Spores by Chronic Obstructive Pulmonary Disease GM-CSFâ€“ and M-CSFâ€“derived Macrophages. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 271-273.	1.4	18
20	Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study. Thorax, 2018, 73, 331-338.	2.7	101
21	Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 739-750.	2.5	53
22	Downregulation of MicroRNA-126 Augments DNA Damage Response in Cigarette Smokers and Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 665-668.	2.5	36
23	Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function. International Journal of COPD, 2018, Volume 13, 2883-2897.	0.9	13
24	Pre-clinical Pharmacokinetic and Metabolomic Analyses of Isorhapontigenin, a Dietary Resveratrol Derivative. Frontiers in Pharmacology, 2018, 9, 753.	1.6	28
25	The dynamic shuttling of SIRT1 between cytoplasm and nuclei in bronchial epithelial cells by single and repeated cigarette smoke exposure. PLoS ONE, 2018, 13, e0193921.	1.1	49
26	Macrophage Dysfunction in Respiratory Disease. Results and Problems in Cell Differentiation, 2017, 62, 299-313.	0.2	68
27	Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L230-L239.	1.3	47
28	Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease Macrophages. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 845-855.	2.5	70
29	Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroidâ€independent mechanism. British Journal of Pharmacology, 2017, 174, 2043-2059.	2.7	56
30	Catalog of Differentially Expressed Long Non-Coding RNA following Activation of Human and Mouse Innate Immune Response. Frontiers in Immunology, 2017, 8, 1038.	2.2	66
31	Correcting the â€œWanderingâ€•Neutrophil with Statins. A Novel Antiaging Strategy?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1243-1244.	2.5	0
32	Oxidative stress dependent microRNA-34a activation via PI3KÎ± reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells. Scientific Reports, 2016, 6, 35871.	1.6	130
33	Could Protecting the Immunoproteasome Reduce Exacerbations in Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1188-1190.	2.5	1
34	Now We Know Who You Are: A Clear Description of Mononuclear Phagocyte Subsets in the Human Lung. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 594-596.	2.5	5
35	Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. European Respiratory Journal, 2016, 47, 1093-1102.	3.1	53
36	Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. PLoS ONE, 2016, 11, e0163139.	1.1	49

#	Article	IF	Citations
37	Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells. PLoS ONE, 2015, 10, e0128757.	1.1	44
38	Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2014, 133, 207-216.e11.	1.5	51
39	Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses. Advanced Drug Delivery Reviews, 2014, 71, 15-33.	6.6	72
40	Impaired macrophage phagocytosis of bacteria in severe asthma. Respiratory Research, 2014, 15, 72.	1.4	85
41	The Lipidome: A New Player in Chronic Obstructive Pulmonary Disease Pathophysiology?. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 124-125.	2.5	3
42	Long non-coding RNAs and enhancer RNAs regulate the lipopolysaccharide-induced inflammatory response in human monocytes. Nature Communications, 2014, 5, 3979.	5.8	281
43	A role for M2 and M3 muscarinic receptors in the contraction of rat and human small airways. European Journal of Pharmacology, 2013, 702, 109-115.	1.7	26
44	Immunopathogenesis of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2013, 19, 95-102.	1.2	59
45	Defective Phagocytosis in Airways Disease. Chest, 2012, 141, 1055-1062.	0.4	157
46	Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochemical and Biophysical Research Communications, 2011, 406, 292-298.	1.0	181
47	Regulation of IL-17 in chronic inflammation in the human lung. Clinical Science, 2011, 120, 515-524.	1.8	39
48	Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages. European Respiratory Journal, 2010, 36, 178-186.	3.1	54
49	Expression of Transient Receptor Potential C6 Channels in Human Lung Macrophages. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 296-304.	1.4	55
50	Novel targets and drugs in inflammatory lung disease. Current Opinion in Pharmacology, 2008, 8, 219-221.	1.7	12
51	Different Mitogen-Activated Protein Kinase-Dependent Cytokine Responses in Cells of the Monocyte Lineage. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 306-312.	1.3	63
52	Th17 Cells in Airway Diseases. Current Molecular Medicine, 2008, 8, 416-426.	0.6	79
53	CXCR3 and CCR5 Chemokines in Induced Sputum From Patients With COPD. Chest, 2008, 133, 26-33.	0.4	140
54	The Role of Ĩ¹B Kinase 2, but Not Activation of NF-Ĩ¹B, in the Release of CXCR3 Ligands from IFN-Ĩ³-Stimulated Human Bronchial Epithelial Cells. Journal of Immunology, 2007, 179, 6237-6245.	0.4	43

#	Article	IF	Citations
55	Phytoceuticals: the new â€˜physic gardenâ€™ for asthma and chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2007, 1, 227-246.	1.0	4
56	The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation?. , 2007, 115, 208-222.		144
57	Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends in Pharmacological Sciences, 2006, 27, 546-553.	4.0	120
58	Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. British Journal of Pharmacology, 2006, 149, 393-404.	2.7	91
59	Analysis of the Dissociated Steroid RU24858 Does Not Exclude a Role for Inducible Genes in the Anti-Inflammatory Actions of Glucocorticoids. Molecular Pharmacology, 2006, 70, 2084-2095.	1.0	61
60	Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NFâ€ºBâ€independent mechanism. FASEB Journal, 2005, 19, 1-22.	0.2	153
61	Chemokines and their Receptors as Targets for the Treatment of COPD. Current Respiratory Medicine Reviews, 2005, 1, 15-32.	0.1	4
62	Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 287, L774-L783.	1.3	297
63	Exhaled Nitric Oxide and Hydrogen Peroxide Concentrations in Asthmatic Smokers. Respiration, 2004, 71, 463-468.	1.2	72
64	Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. Journal of Leukocyte Biology, 2004, 76, 441-450.	1.5	144
65	Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E2 release. FEBS Journal, 2004, 271, 4042-4052.	0.2	44
66	Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes. Molecular Pharmacology, 2004, 66, 1679-1689.	1.0	160
67	Acidic mammalian chitinase â€“ a potential target for asthma therapy. Trends in Pharmacological Sciences, 2004, 25, 509-511.	4.0	76
68	Therapy for Chronic Obstructive Pulmonary Disease in the 21st Century. Drugs, 2003, 63, 1973-1998.	4.9	74
69	Antiproteases and retinoids for treatment of chronic obstructive pulmonary disease. Expert Opinion on Therapeutic Patents, 2003, 13, 1345-1372.	2.4	10
70	A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB Journal, 2003, 17, 1298-1300.	0.2	193
71	Impaired Inhibition by Dexamethasone of Cytokine Release by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 24-31.	2.5	281
72	Nitric Oxide Metabolites Are Not Reduced in Exhaled Breath Condensate of Patients With Primary Ciliary Dyskinesia*. Chest, 2003, 124, 633-638.	0.4	48

#	Article	IF	Citations
73	Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L867-L873.	1.3	208
74	Expression and Regulation of Inducible Nitric Oxide Synthase from Human Primary Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 144-151.	1.4	78
75	Release and Activity of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 602-609.	1.4	386
76	Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1371-1376.	2.5	163
77	Regulation of kinin receptors in airway epithelial cells by inflammatory cytokines and dexamethasone. European Journal of Pharmacology, 2002, 441, 193-202.	1.7	29
78	Chronic systemic administration of salmeterol to rats promotes pulmonary Î²2 -adrenoceptor desensitization and down-regulation of GsÎ±. British Journal of Pharmacology, 2001, 132, 1261-1270.	2.7	30
79	Expression of Heme Oxygenase in Human Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 295-303.	1.4	88
80	Albuterol-induced downregulation of GsÎ± accounts for pulmonary Î²2-adrenoceptor desensitization in vivo. Journal of Clinical Investigation, 2000, 106, 125-135.	3.9	64
81	Constitutive expressions of type I NOS in human airway smooth muscle cells: evidence for an antiproliferative role. FASEB Journal, 1999, 13, 1810-1816.	0.2	65
82	Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells. FEBS Journal, 1998, 254, 81-89.	0.2	93
83	Arginine-Specific Mono(ADP-Ribosyl)Transferase Activity in Human Neutrophil Polymorphs. Advances in Experimental Medicine and Biology, 1997, 419, 241-244.	0.8	6
84	Reduction by inhibitors of mono(ADPâ€ribosyl)transferase of chemotaxis in human neutrophil leucocytes by inhibition of the assembly of filamentous actin. British Journal of Pharmacology, 1996, 118, 1111-1118.	2.7	19
85	Arginine-specific mono(ADP-ribosyl)transferase activity on the surface of human polymorphonuclear neutrophil leucocytes. Biochemical Journal, 1996, 315, 635-641.	1.7	32
86	Excursions in biomedical mass spectrometry. British Journal of Clinical Pharmacology, 1996, 42, 119-126.	1.1	5
87	A possible role for mono(ADP-ribosyl)transferase in the signalling pathway mediating neutrophil chemotaxis. British Journal of Clinical Pharmacology, 1996, 42, 99-106.	1.1	16
88	Inhibition of ADP-ribosyltransferase increases synthesis of GsÎ± in neuroblastoma Ã— glioma hybrid cells and reverses iloprost-dependent heterologous loss of fluoride-sensitive adenylate cyclase. Biochemical Pharmacology, 1995, 49, 767-776.	2.0	3
89	Loss of responses to bradykinin, ATP or carbachol follows depletion of a shared pool of calcium ions. European Journal of Pharmacology, 1994, 267, 161-166.	2.7	5
90	Endogenous substrates and functional role of eukaryotic mono(ADP-ribosyl)transferases. Biochemical Pharmacology, 1994, 48, 1669-1675.	2.0	4

#	Article	IF	Citations
91	Opiate-Dependent Changes in the Sensitivity of Adenylate Cyclase to Stimulatory Agonists and 5'-Guanylylimidodiphosphate Are Independent of G Protein Abundance and Eukaryotic ADP-Ribosyltransferase Activity in NG108-15 Cells. Journal of Neurochemistry, 1992, 58, 688-693.	2.1	4
92	Differential growth characteristics of adipocyte percursor cells derived from the white adipose tissue of the chicken (Gallus domesticus). Biochemical Society Transactions, 1989, 17, 1119-1120.	1.6	1